News Search Results
Jun 15, 2026, 08:30 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well
More news about: Neurocrine Biosciences, Inc.
Jun 09, 2026, 18:16 ET Rockefeller Foundation Mobilizes $450M+ Investments for U.S. Communities during Big Bets for America Convenings
landscape, fuel economic activity in under-invested neighborhoods, and has already helped advance more than 200 affordable homes since March 2025. With Huntington's commitment, CHIF has now realized more than half of its $100 million investment goal.MSCHF Announces New Permanent
More news about: The Rockefeller Foundation
Jun 09, 2026, 16:00 ET Huntington Bank Opens First Branch in Kernersville
Located at 250 E. Mountain St., the newly built, freestanding location marks Huntington's fourth full-service branch in North Carolina's Triad area. It also represents Huntington's 10th full-service branch in the Carolinas and reflects the bank's ongoing execution of its strategy
More news about: Huntington Bank
Jun 08, 2026, 16:05 ET Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients
controlled (tardive dyskinesia). involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of involuntary movements, and do not treat other symptoms of Huntington's disease, such as problems with thinking or emotions. It is not known
More news about: Neurocrine Biosciences, Inc.
Jun 08, 2026, 08:30 ET Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities
controlled (tardive dyskinesia). involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of involuntary movements, and do not treat other symptoms of Huntington's disease, such as problems with thinking or emotions. It is not known
More news about: Neurocrine Biosciences, Inc.
Jun 04, 2026, 09:00 ET Huntington Bank Ranks No. 1 in Customer Satisfaction in the JD Power 2026 U.S. Online Banking and U.S. Mobile App Satisfaction Studies
2026 Online Banking Satisfaction StudySM and the JD Power 2026 Mobile App Satisfaction StudySM. This recognition reflects Huntington's focus on delivering customer-centric and intuitive digital experiences.
More news about: Huntington Bank
Jun 03, 2026, 08:30 ET Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well
More news about: Neurocrine Biosciences, Inc.
Jun 02, 2026, 04:19 ET Skyhawk Therapeutics gibt Zwölfmonats-Zwischenergebnisse der klinischen Phase-1/2-Studie zu SKY-0515 bei der Huntington-Krankheit bekannt
Die Zwölfmonatsergebnisse zeigten eine Verbesserung der Werte auf der Composite Unified Huntington's Disease Rating Scale (cUHDRS) um +0,38 gegenüber dem Ausgangswert, verglichen mit einem erwarteten Rückgang von -0,92 Punkten in den nach Propensity Score gewichteten Analysen zum
More news about: Skyhawk Therapeutics
Jun 01, 2026, 11:15 ET Huntington Bank to Serve as Official Sponsor of the 2026 Special Olympics USA Games
golf ambassadors, introduced in connection with its role as an official sponsor of the PGA TOUR University. Together, these efforts demonstrate Huntington's focus on connecting with communities through shared experiences and supporting initiatives that bring people together.For more information
More news about: Huntington Bank
Jun 01, 2026, 06:30 ET Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
Twelve-month findings showed improvement in Composite Unified Huntington's Disease Rating Scale (cUHDRS) scores from baseline of +0.38, compared to an expected decline of -0.92 points in propensity score-weighted natural history analyses of symptomatic patientsSKY-0515
More news about: Skyhawk Therapeutics
Jun 01, 2026, 06:30 ET Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
Twelve-month findings showed improvement in Composite Unified Huntington's Disease Rating Scale (cUHDRS) scores from baseline of +0.38, compared to an expected decline of -0.92 points in propensity score-weighted natural history analyses of symptomatic patientsSKY-0515
More news about: Skyhawk Therapeutics
May 27, 2026, 06:30 ET Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
served as General Manager of Roche Czech Republic, where he led full operations and commercial strategy. Earlier, he served as Lifecycle Leader for Huntington's disease within Roche's neuroscience portfolio.Mr. Lundgren spent more than a decade at Genentech in roles of increasing responsibility, including
More news about: Immunic, Inc.
May 26, 2026, 16:02 ET Huntington Bancshares Incorporated to Present at the 2026 Morgan Stanley US Financials Conference
Webcast InformationInterested investors may access the live audio webcast in the investor relations section of Huntington's website (
More news about: Huntington Bancshares Incorporated
May 26, 2026, 16:01 ET Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well
More news about: Neurocrine Biosciences, Inc.
May 21, 2026, 15:00 ET Huntington Bank Awards More Than 250 Mississippi Educators with Year-long Professional Development Experience
Educators from Jackson, Tupelo and Lee County school districts selected to participate in Huntington's Ignite the Classroom InitiativeTUPELO, Miss. and JACKSON, Miss., May 21, 2026 /PRNewswire/
More news about: Huntington Bank
May 20, 2026, 16:44 ET Huntington Bancshares Incorporated to Present at the 2026 Sanford Bernstein Strategic Decisions Conference
Webcast InformationInterested investors may access the live audio webcast in the investor relations section of Huntington's website (www.huntington-ir.com). A replay of the webcast will be archived on the website.About
More news about: Huntington Bancshares Incorporated
May 19, 2026, 09:49 ET Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1
antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington's disease, as well as several preclinical programs utilizing the company's versatile RNA medicines platform. Driven by the calling to "Reimagine Possible,"
More news about: Alpha-1 Foundation
May 18, 2026, 16:05 ET Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
controlled (tardive dyskinesia). involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of involuntary movements, and do not treat other symptoms of Huntington's disease, such as problems with thinking or emotions. It is not known
More news about: Neurocrine Biosciences, Inc.
May 18, 2026, 08:46 ET Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well
More news about: Neurocrine Biosciences, Inc.
May 14, 2026, 16:13 ET American Society of Gene and Cell Therapy Awards Beverly L. Davidson, PhD, Outstanding Achievement Award
therapies. She is widely recognized for her Huntington's disease research, innovations in vector engineering, and mentorship of the next generation of translational scientists.Major scientific contributions by Dr. Davidson and her team beyond Huntington's include:Discovery
More news about: Children's Hospital of Philadelphia
May 12, 2026, 08:00 ET 28bio Launches CNS-3D Myelinated Organoids to Predict Therapeutic Efficacy
sclerosis, impaired myelin integrity contributes to functional deficits across neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's. This challenge is amplified in cell and gene therapies, where restoring or preserving myelin requires precise targeting of oligodendrocytes and
More news about: 28bio
May 11, 2026, 14:01 ET Huntington Bank Opens First Branch in Greensboro
Located at 1401 Four Seasons Station Drive, the newly built, freestanding location marks Huntington's third full-service branch in the Triad. The branch is part of Huntington's previously announced plans to open approximately 55 branches in North Carolina and South Carolina as it brings
More news about: Huntington Bank
May 11, 2026, 12:41 ET DNA Polymerase Market to Reach USD 725.8 Million by 2035 as Molecular Diagnostics and High-Fidelity Enzymes Accelerate Precision Genomics
disorders and infectious diseases is emerging as a primary growth catalyst for the DNA polymerase industry. Conditions such as cystic fibrosis, Huntington's disease, sickle cell anemia, HIV, tuberculosis, influenza, and malaria are increasing the need for highly sensitive molecular diagnostic solutions.PCR-based
More news about: Future Market Insights
May 07, 2026, 16:01 ET PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
francs)cUHDRS: Composite Unified Huntington's Disease Rating Scale DMD: Duchenne muscular dystrophyFA: Friedreich's ataxiaFDA: US Food and Drug AdministrationGAAP: Generally Accepted Accounting PrinciplesHD: Huntington's diseasemFARS: Modified Friedreich's
More news about: PTC Therapeutics, Inc.
May 06, 2026, 08:30 ET Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
psychiatric and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.